Sentences with phrase «cell replacement therapy inunilateral»
ViaCyte's stem cell replacement therapy for the treatment of type 1 diabetes was highlighted in a June 2012 Popular Science article on artificial organs.
http://viacyte.com/
The company is the first to advance an encapsulated islet cell replacement therapy for type -LSB-...]
As the first company to advance a cell replacement therapy for type 1 diabetes into the clinic, ViaCyte is committed to developing a functional cure for all type 1 diabetes patients.
«In particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell - derived cell replacement therapy.
Diabetes Forecast highlighted ViaCyte's first - of - a-kind islet cell replacement therapy in an article discussing twelve innovative products being developed to treat and manage type 1 diabetes.
Understanding how heart muscle cells, or cardiomyocytes, change in space improves efforts for studying disease, screening drugs and conducting cell replacement therapy for future space missions.
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
«The PEC - Direct islet cell replacement therapy is designed to help patients with the most urgent medical need.»
The Company's pluripotent stem cell - derived islet cell replacement therapy, the PEC - Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.
The initial phase of clinical investigation is focusing on the safety of the cell replacement therapy combination products in patients.
With the STEP ONE trial underway, and the addition of W. L. Gore & Associates as collaborators to optimize the Encaptra ® cell delivery system, ViaCyte felt that the PEC - Direct approach might be the most rapid way to get the invaluable PEC - 01 cell replacement therapy to those who need it most.
ViaCyte's VC - 01 ™ product candidate, a first - in - class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC - 01 Combination Product in Type One Diabetes.
STEP ONE is the first trial in the world investigating a stem cell - derived beta cell replacement therapy for diabetes.
The first - in - human STEP ONE * trial is evaluating the safety and efficacy of ViaCyte's PEC - Encap (a.k.a. VC - 01 ™) product candidate, a stem cell - derived, encapsulated cell replacement therapy.
Similarly, in the laboratory we've been studying cell replacement therapy.
JDRF and ViaCyte Announce Support for Development of PEC - Direct Cell Replacement Therapy for Type 1 Diabetes
The company is the first to advance an encapsulated islet cell replacement therapy for type 1 diabetes into clinical trials.
For the first time, researchers demonstrate long term success of a cell replacement therapy using autologous induced pluripotent stem cell derivatives
The cells generated in the Zeng lab may not only provide a potential unlimited source for cell replacement therapy for Parkinson's disease, but also offer an unprecedented opportunity to develop screening models for assessing small molecule drugs and to clarify the mechanisms of disease.
ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.
«The loss of insulin - producing beta cells leads to type 1 diabetes, making it an ideal target for cell replacement therapy,» said James Shapiro, MD, PhD, FRCSC, Director of the Clinical Islet Transplant Program, University of Alberta.
«Our long term goal is to develop a personalized cell replacement therapy using a patient's own cells to treat boys with Duchenne,» said Hicks.
The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
«Skeletal muscle created from stem cells: Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy.»
However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.
With these findings, Helmholtz Zentrum München scientists have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes.
An EU - funded research project («HumEn»), in which Lickert and his team are participating, shall provide further insights in the field of beta - cell replacement therapy.
«For the broad application of stem cell - derived pituitary cells in the future, cell replacement therapy may need to be customized to the specific needs of a given patient population,» Zimmer says.
But in patients with type 1 diabetes, beta - cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.
But for cell replacement therapy to realize its potential, I anticipate that scientists must solve the developmental code, the set of rules that govern the formation of tissues, organs, and beings from the original single cell — the zygote.
Several clinical trials are testing cell replacement therapies to treat spinal cord injuries.
Our long - term goal, therefore, is to explore the potential to genetically disrupt both ccr5 and cxcr4 for cell replacement therapies in HIV infected individuals, and in the case of cxcr4 do so in a way that specifically targets CXCR4 on T cells and not the many other cell types on which it is expressed.
The third and final day of the 2016 Huntington's Disease Therapeutics Conference brings updates on cell replacement therapies including stem cells; and new ways to assess and model the progression of HD to help understand it and run crucial clinical trials.
This brings together the two leaders in cell replacement therapies for diabetes.
Our research goal is to understand the molecular and cellular events required for pancreatic β - cell regeneration, and apply this knowledge towards the development of cell replacement therapies for diabetes.
He is particularly interested in the mechanisms and molecules that regulate neural stem cell maintenance, cell fate programming and neural stem cell replacement therapies.
There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.
«These events offer several venues and platforms to share the exciting progress ViaCyte is making in developing novel cell replacement therapies for diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
In addition, we use our expertise to facilitate the development of functionally mature beta cells from embryonic stem cells for cell replacement therapies of type 1 diabetes.
Cell replacement therapies require clinically safe stem cells that can be used to generate many (possibly all) types of cells.
«We are grateful to CIRM and the citizens of California for their continued support of our potentially transformative stem cell - derived, cell replacement therapies for diabetes,» said Paul Laikind, Ph.D., President and CEO of ViaCyte.
ViaCyte has two stem cell - based islet cell replacement therapies in clinical development.
Information on the clinical testing of ViaCyte's implantable cell replacement therapies can be found at Clinicaltrials.gov.
«JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC - Direct islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.
Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapies for Type 1 Diabetes
«You can manipulate stem cells and propagate them in a dish, but many recipients of stem cell replacement therapies will be older individuals.
Given our extensive experiences in neuronal differentiation of hESCs [6], [7], [8] and the potential application of hESC - derived neurons in cell replacement therapies for neurodegenerative diseases, we designed a set of experiments aimed at developing a hESC - based automated assay for screening small molecules that have differential toxicity to hESC - derived NSCs and their differentiated neural progenies.
Importantly, because it is already approved for clinical use, amiodarone HCL may have clinical applications in cell replacement therapies by selectively removing only the unwanted undifferentiated NSCs during the pre-transplant period.
Not exact matches
«This research has broad impact, because by deepening our understanding of cell reprogramming we have the potential to improve disease modeling and the generation of better sources of patient - specific specialized cells suitable for replacement therapy,» said Plath.
Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.